Front Endocrinol (Lausanne) 14(12):735824 [DOI] [PMC free article] [PubMed] [Google Scholar] 78.Cheng L, Hu Y, Li YY, Cao X, Bai N, Lu TT, Li GQ, Li N, Wang AN, Mao XM (2019) Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
It is ideal for mild loosening of the face, neck, and body
(34) Given the increased risk of sarcopenia, osteoporosis, and frailty in older adults, future research should explore the long-term effects of GLP-1 receptor agonists on musculoskeletal health in this population, alongside their established systemic benefits
Bone (2002) 30(1):30713.10.1016/S8756-3282(01)00662-7 17 Nuche-BerenguerBMorenoPEsbritPDapiaSCaeiroJRCancelasJet alEffect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states